Education
About Us
Working with TipRanks
Follow Us
Urogen Pharma (URGN)
NASDAQ:URGN
URGN Analyst Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
URGN Stock 12 Month Forecast
Average Price Target
$39.40
▲(56.72% Upside)
| Highest Price Target$55.00 | Average Price Target$39.40 | Lowest Price Target$31.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$40
Buy
59.11%
Upside
Reiterated
11/10/25
UroGen Pharma's Promising Outlook: Buy Rating Backed by ZUSDURI's Growth and Strong Financial HealthValuation methodology, risks and uncertainties. We employ a discounted cash flow (DCF)-based approach to valuing UroGen Pharma shares that derives a risk-adjusted net present value (rNPV) of $2.2B solely for UGN-101 and UGN-102, which yields a price target of $40 per share. Our assumptions include an 11.5% discount rate, a 2% terminal rate of decline and a 23% effective tax rate.
Oppenheimer
$31
Buy
23.31%
Upside
Reiterated
11/07/25
Ladenburg Thalmann & Co.
$55
Buy
118.77%
Upside
Reiterated
11/07/25
TD Cowen
$35
Buy
39.22%
Upside
Reiterated
11/06/25
Urogen Pharma's Promising Growth and Demand Surge Support Buy RatingWe expect accelerating demand as the company works through the hurdles and getting physicians up to speed. This can be seen with the 54 unique Zusduri prescribers, of which 16 are repeat prescribers. As such, we estimate Q4 Zusduri sales of $12MM in anticipation of continued demand and expect +20-30% Q/Q growth in each quarter during 2026, in-line with KOL commentary (discussed below) On timing, it now takes 4-6 weeks from enrollment to dosing, and should improve to 2-3 weeks next year. Remittance (time to paid claims) is at 50-60 days, and should improve to 15-20 days throughout H1:2026. UroGen Is Taking A Management believes that there will be two stages to the launch encompassing the periods before and after the expected permanent J code, which was granted by CMS in October and will go into effect January 1st.
Piper Sandler
$36
Buy
43.20%
Upside
Reiterated
08/29/25
Guggenheim
$30→$32
Buy
27.29%
Upside
Reiterated
08/07/25
Scotiabank
$47
Buy
86.95%
Upside
Reiterated
08/06/25
Goldman Sachs
$3→$16
Hold
-36.36%
Downside
Reiterated
06/13/25
D. Boral Capital
$25
Buy
-0.56%
Downside
Reiterated
06/12/25
Raymond James
$40→$36
Buy
43.20%
Upside
Reiterated
03/11/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$40
Buy
59.11%
Upside
Reiterated
11/10/25
UroGen Pharma's Promising Outlook: Buy Rating Backed by ZUSDURI's Growth and Strong Financial HealthValuation methodology, risks and uncertainties. We employ a discounted cash flow (DCF)-based approach to valuing UroGen Pharma shares that derives a risk-adjusted net present value (rNPV) of $2.2B solely for UGN-101 and UGN-102, which yields a price target of $40 per share. Our assumptions include an 11.5% discount rate, a 2% terminal rate of decline and a 23% effective tax rate.
Oppenheimer
$31
Buy
23.31%
Upside
Reiterated
11/07/25
Ladenburg Thalmann & Co.
$55
Buy
118.77%
Upside
Reiterated
11/07/25
TD Cowen
$35
Buy
39.22%
Upside
Reiterated
11/06/25
Urogen Pharma's Promising Growth and Demand Surge Support Buy RatingWe expect accelerating demand as the company works through the hurdles and getting physicians up to speed. This can be seen with the 54 unique Zusduri prescribers, of which 16 are repeat prescribers. As such, we estimate Q4 Zusduri sales of $12MM in anticipation of continued demand and expect +20-30% Q/Q growth in each quarter during 2026, in-line with KOL commentary (discussed below) On timing, it now takes 4-6 weeks from enrollment to dosing, and should improve to 2-3 weeks next year. Remittance (time to paid claims) is at 50-60 days, and should improve to 15-20 days throughout H1:2026. UroGen Is Taking A Management believes that there will be two stages to the launch encompassing the periods before and after the expected permanent J code, which was granted by CMS in October and will go into effect January 1st.
Piper Sandler
$36
Buy
43.20%
Upside
Reiterated
08/29/25
Guggenheim
$30→$32
Buy
27.29%
Upside
Reiterated
08/07/25
Scotiabank
$47
Buy
86.95%
Upside
Reiterated
08/06/25
Goldman Sachs
$3→$16
Hold
-36.36%
Downside
Reiterated
06/13/25
D. Boral Capital
$25
Buy
-0.56%
Downside
Reiterated
06/12/25
Raymond James
$40→$36
Buy
43.20%
Upside
Reiterated
03/11/25
Best Analysts Covering Urogen Pharma
1 Month
xxx
Success Rate
13/24 ratings generated profit
Average Return
+17.35%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 54.17% of your transactions generating a profit, with an average return of +17.35% per trade.
3 Months
xxx
Success Rate
14/24 ratings generated profit
Average Return
+28.09%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 58.33% of your transactions generating a profit, with an average return of +28.09% per trade.
1 Year
Success Rate
9/12 ratings generated profit
Average Return
+24.43%
reiterated a buy rating 8 days ago
Copying Tara Bancroft's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +24.43% per trade.
2 Years
xxx
Success Rate
12/12 ratings generated profit
Average Return
+41.47%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +41.47% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
URGN Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
21
20
13
11
6
Buy
0
0
0
0
2
Hold
18
12
7
5
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
39
32
20
16
11
Each month's total comprises the sum of three months' worth of ratings.
URGN Financial Forecast
URGN Stock Forecast FAQ
What is URGN’s average 12-month price target, according to analysts?
Based on analyst ratings, Urogen Pharma’s 12-month average price target is 39.40.
What is URGN’s upside potential, based on the analysts’ average price target?
Urogen Pharma has 56.72% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is URGN a Buy, Sell or Hold?
Urogen Pharma has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
What is Urogen Pharma’s price target?
The average price target for Urogen Pharma is 39.40. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $55.00 ,the lowest forecast is $31.00. The average price target represents 56.72% Increase from the current price of $25.14.
The highest analyst price target is $55.00 ,the lowest forecast is $31.00. The average price target represents 56.72% Increase from the current price of $25.14.
What do analysts say about Urogen Pharma?
Urogen Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of URGN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.